Clinical Trial Update: Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating gefitinib for USP8-mutated Cushing's disease, including patients with corticotrophin adenoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corticotrophin Adenoma
• Cushing Disease

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: Huashan Hospital | Conditions: Cushing's Disease, Corticotrophin Adenoma | Phase 2 | Status: UNKNOWN